Document is current

Article History

Received: 31 August 2023

Accepted: 25 December 2023

First Online: 13 February 2024

Declarations

:

: JFH: advisory/consulting for Bristol Myers Squibb, AstraZeneca, Pfizer, Novartis, Eli-Lilly, and Merck; member of a DMC Committee for Bristol Myers Squibb.PAO: grants/research support recipient from Neon Therapeutics, Bristol Myers Squibb, Merck, AstraZeneca /MedImmune, ArmoBiosciences, Pfizer, Novartis, CytomX, Genentech, Celldex; ad hoc consulting for Neon Therapeutics, Bristol Myers Squibb, Merck, ArmoBiosciences, Pfizer, Novartis, CytomX, Genentech, Celldex, Array; scientific advisory board for Evaxion, Phio, and Immunetune.ARH: advisory/consulting and research support from Genentech/Roche, Merck, GSK, Bristol Myers Squibb, Novartis, Boston Biomedical, Boehringer Ingelheim.ZL: advisory/board member and honorarium recipient for Boehringer Ingelheim.MM: equity in Navinta.CHM, VD, and MB: former employees of and hold stocks/shares in GSK.XJ, NOK, SH: employees of and hold stocks/shares in GSK.DPZ: advisory for Blueprint Medicines and Prelude Therapeutics; consulting for Macrogenics; research support for role as principal investigator from Merck, Bristol Myers Squibb, AstraZeneca, GSK, Aduro, Astellas, Macrogenics, Lilly, Bicara, Checkmate Pharma, Novasenta.

: GSK makes available anonymized individual participant data and associated documents from interventional clinical studies that evaluate medicines, upon approval of proposals submitted to:

: The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines following approval by ethics committees and institutional review boards at each study site.

: All patients provided written informed consent.